Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

Cancer Medicine, Год журнала: 2024, Номер 13(10)

Опубликована: Май 1, 2024

Abstract Background Cyclin‐dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy (ET) become standard‐of‐care for patients with hormone receptor‐positive, human epidermal growth factor receptor‐2 negative (HR+/HER2−) metastatic breast cancer (MBC). However, the optimal therapeutic paradigm after progression on CDK4/6 remains unclear. This study aimed to evaluate efficacy and safety of abemaciclib switching ET versus chemotherapy prior palbociclib‐based in Chinese HR+/HER2− MBC. Methods From 414 consecutive MBC who had been treated palbociclib from September 2018 May 2022 Peking University Cancer Hospital, we identified 80 received or palbociclib, matched age, original stage at diagnosis, disease‐free interval, tumor burden 1:1 ratio. The primary endpoint was progression‐free survival (PFS) compared using Kaplan–Meier method. A Cox proportional hazard model performed identify clinical factors associated PFS group. Results median 6.0 months (95% confidence interval [CI]: 3.94–8.06) group 4.0 CI, 2.52–5.49) ( p = 0.667). And, there no difference between sequential nonsequential arm (6.0 vs. months) though fewer lines systemic longer arm. as first‐line a significantly ≥2nd‐line (11.0 5.0 months, 0.043). Based multivariable analysis, ER+/PR+ an independent PFS. There significant overall groups 0.069). Conclusion Our findings indicate that might be one feasible treatment options addition chemotherapy.

Язык: Английский

---

Application of a CYP1B1-Targeted NIR Probe for Breast Cancer Diagnosis, Surgical Navigation, and CYP1B1-Associated Chemotherapy Resistance Monitoring

Molecular Pharmaceutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 30, 2025

Early detection and precise treatment for breast cancer are crucial, given its high global incidence rate. Hence, the development of novel imaging targets is essential diagnosing monitoring resistance to chemotherapy, which pivotal achieving personalized patients. In our previous work, we successfully developed a near-infrared (NIR) probe 1 CYP1B1-targeted imaging. this study, aimed investigate utility as NIR fluorescence photoacoustic dual-mode surveillance cancer. Western blotting cell lines has confirmed that CYP1B1 widely expressed in gynecological vitro capability tracking CYP1B1-positive tumor cells was validated by using confocal microscopy. Further studies, including vivo dual-model ex biological distribution analysis on triple-negative xenograft mouse model, demonstrated selectively accumulated tissue within early 0.5 h postinjection. The results surgical resection experiment revealed could be entirely removed under guidance imaging, thereby indicating probe's efficacy navigation. expression found upregulated adriamycin (ADR)-resistant cells, MCF-7/ADR. Consequently, sensitivity overexpressed MCF-7/1B1, ADR significantly reduced, with an IC50 value 0.586 ± 0.0934 μM, compared parental MCF-7 0.183 0.0444 μM. assays conducted MCF-7/ADR tumor-bearing mice specifically enriched sites, suggesting potential chemotherapy This study expands scope application 1, establishing diagnosis through fluorescence-photoacoustic resistance, resection. strategy paves way approaches

Язык: Английский

---

CDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status

Cancers, Год журнала: 2025, Номер 17(6), С. 1039 - 1039

Опубликована: Март 20, 2025

Breast cancer is the most frequently diagnosed neoplasm in world. It can be classified into four main subtypes, each of them showing differences expression hormone receptor (HR), human epidermal growth factor 2 (HER2), and cell metabolism. Since 2015, when The U.S. Food Drug Administration (FDA) approved first cyclin-dependent kinase 4 6 (CDK4/6) inhibitor that regulates cycle, treatment HR+/HER2− BC has become much more effective. Currently, palbociclib, ribociclib, abemaciclib are often used both combination with endocrine therapy as well monotherapy. Their application been extensively verified many clinical trials such PALOMA-1,2,3, MONALEESA-1,2,3,7, MONARCH-1,2,3, which allowed verification their effectiveness, dosage, adverse effects. Subsequent studies, MonarchE NATALEE, examined role these inhibitors adjuvant therapy, at verifying safety. Moreover, dalpiciclib being investigated treatment. This article will summarize efficacy, recommendations, toxicity profile between also discuss possibility using breast cancer.

Язык: Английский

---

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study

Annals of Oncology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

---